Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hushen Jiedu recipe is a Traditional Chinese Medicine (TCM) formulation developed by the Ningbo Hospital of Traditional Chinese Medicine. It is specifically designed to treat severe COVID-19 infections in patients with underlying stage 4–5 chronic kidney disease (CKD) or those on dialysis (end-stage renal disease). The recipe's name reflects its primary therapeutic goals: 'Hushen' (protecting the kidney) and 'Jiedu' (detoxifying). It is typically administered as an oral decoction alongside standard Western medical care. The formulation aims to mitigate the severity of viral infection while preserving renal function and managing the systemic inflammatory response in a highly vulnerable patient population. It is currently being evaluated in multicenter randomized controlled trials to determine its efficacy and safety in improving clinical outcomes for this specific high-risk group.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hushen Jiedu recipe.